Hosted on MSN

Novo Nordisk plans Wegovy vial launch to counter Eli Lilly, target broader obesity market

Novo Nordisk A/S NVO plans to start selling its blockbuster obesity drug Wegovy in vials, marking its latest effort to strengthen its position against rival Eli Lilly and Co. LLY as competition ...
Hosted on MSN

Wegovy pill sales smash forecasts, sending Novo Nordisk stock higher

Novo hiked its 2026 full-year guidance on the back of increased expectations for GLP-1 product sales, saying it now expects adjusted sales and profit to contract between 4% and 12%. Novo said ...